701,754 Shares in COMPASS Pathways PLC Sponsored ADR $CMPS Bought by Driehaus Capital Management LLC

Key Points

• Driehaus Capital Management LLC acquired 701,754 shares of COMPASS Pathways PLC, totaling approximately $2,007,000, representing 0.76% ownership at the end of the quarter.
• Several institutional investors, including Jane Street Group LLC and ARK Investment Management LLC, have significantly increased their stakes in COMPASS Pathways recently, indicating growing interest in the company.
• COMPASS Pathways reported a loss of $0.38 per share in its recent quarterly earnings, slightly missing analysts’ expectations and prompting a consensus price target of $16.29 from investment analysts.

Driehaus Capital Management LLC bought a new position in COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The firm bought 701,754 shares of the company's stock, valued at approximately $2,007,000. Driehaus Capital Management LLC owned 0.76% of COMPASS Pathways at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of CMPS. Jane Street Group LLC lifted its position in COMPASS Pathways by 72.7% during the 4th quarter. Jane Street Group LLC now owns 51,815 shares of the company's stock valued at $196,000 after acquiring an additional 21,815 shares during the period. Balyasny Asset Management L.P. purchased a new position in COMPASS Pathways in the fourth quarter worth about $2,458,000. Cubist Systematic Strategies LLC raised its holdings in COMPASS Pathways by 205.7% in the fourth quarter. Cubist Systematic Strategies LLC now owns 126,636 shares of the company's stock worth $479,000 after buying an additional 85,213 shares during the last quarter. Integral Health Asset Management LLC purchased a new position in COMPASS Pathways in the fourth quarter worth about $756,000. Finally, Point72 Asset Management L.P. raised its holdings in COMPASS Pathways by 15.4% in the fourth quarter. Point72 Asset Management L.P. now owns 67,999 shares of the company's stock worth $257,000 after buying an additional 9,099 shares during the last quarter. 46.19% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on CMPS shares. Canaccord Genuity Group reiterated a "buy" rating and issued a $15.00 price target on shares of COMPASS Pathways in a research note on Friday, August 1st. HC Wainwright cut their target price on shares of COMPASS Pathways from $45.00 to $40.00 and set a "buy" rating for the company in a research report on Monday, August 4th. Cantor Fitzgerald restated an "overweight" rating and set a $12.00 target price on shares of COMPASS Pathways in a research report on Tuesday, May 27th. Finally, Evercore ISI restated an "in-line" rating and set a $6.00 target price (down from $11.00) on shares of COMPASS Pathways in a research report on Monday, June 23rd. Six investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $16.29.

COMPASS Pathways Price Performance

Shares of CMPS traded up $0.04 during mid-day trading on Friday, reaching $5.14. The stock had a trading volume of 2,295,315 shares, compared to its average volume of 1,824,367. The firm has a market cap of $493.13 million, a price-to-earnings ratio of -2.79 and a beta of 2.17. COMPASS Pathways PLC Sponsored ADR has a 12 month low of $2.25 and a 12 month high of $7.53. The business has a fifty day moving average of $4.12 and a 200 day moving average of $3.86. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.82 and a current ratio of 8.82.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.01). Equities analysts predict that COMPASS Pathways PLC Sponsored ADR will post -2.33 EPS for the current year.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.